Is Eli Lilly Stock Going to $950? 1 Wall Street Analyst Thinks So.

Is Eli Lilly Stock Going to $950? 1 Wall Street Analyst Thinks So.

While Eli Lilly’s (NYSE: LLY) stock trades for around $770 today, Morgan Stanley analyst Terence Flynn thinks it’ll soon go as high as $950, rising by around 23%. Based on the updated price target he set on Feb. 16, it’s safe to assume that he didn’t think that his previous estimate of $805 was bullish enough to account for the company’s current and future set of opportunities.

The company’s sunny financial guidance for 2024 meshes well with Flynn’s estimate, with management anticipating as much as $41.6 billion in revenue. That implies plenty of growth on top of its trailing-12-month (TTM) haul of $32.1 billion. Here’s how it’ll probably happen.

Zepbound’s ascent will carry this stock skyward

The most important driver of Eli Lilly’s top line this year will be its freshly launched weight loss drug called Zepbound, which was approved on Nov. 8, 2023. In 2023, sales of the medicine, a direct competitor to Novo Nordisk’s blockbuster drug Wegovy, totaled $176 million.

But given that demand is so fierce that both businesses have needed to restrict onboarding new patients so as to ensure an adequate supply of doses for existing patients, this year’s sum will almost certainly be much higher. Sales of Zepbound’s sibling medicine for type 2 diabetes, Mounjaro, will also likely see a continued ramp-up that’s sure to contribute to sharply rising revenue.

Investors have a lot to look forward to this year

Zepbound and Mounjaro are just the latest big earners to be approved from Eli Lilly’s pipeline. Before the end of the year, it should hear back from regulators at the Food and Drug Administration (FDA) regarding whether one of its programs for treating Alzheimer’s disease will be approved. It’ll also be hearing back regarding its atopic dermatitis program — and both of those potential approvals could be significant catalysts for the stock as well.

SPONSORED:

Should you invest $1,000 in Eli Lilly right now?

Before you buy stock in Eli Lilly, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.

See the 10 stocks

*Stock Advisor returns as of February 20, 2024

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.